All News

    Lingering Stress After Follicular Lymphoma Remission is a Challenge

    April 30th 2025, 5:06pm

    Article

    Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue to weigh heavily on me.

    CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer

    April 30th 2025, 4:01pm

    Article

    CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study.

    Larger Tumor Size Linked to Higher Mortality Risk in Brain Cancer

    April 30th 2025, 3:18pm

    Article

    Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.

    SENTI-202 Shows Positive Preliminary Data in Acute Myeloid Leukemia

    April 30th 2025, 1:00pm

    Article

    A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia.

    An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC

    April 29th 2025, 9:00pm

    Article

    The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer.

    Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer

    April 29th 2025, 8:00pm

    Video

    Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer.

    TAR-200 Shows High Response Rates in Bladder Cancer Subset

    April 29th 2025, 7:00pm

    Article

    TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study.

    A Fellow Cancer Survivor Gives Me a Useful Message

    April 29th 2025, 5:00pm

    Article

    A chance meeting with my childhood friend reminded me — and others — that living with cancer means taking things one day at a time.

    FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

    April 29th 2025, 4:04pm

    Article

    The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.

    FDA Fast Tracks INX-315 for Tough-to-Treat Ovarian Cancer

    April 29th 2025, 3:00pm

    Article

    INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.